News OS Therapies Acquires All Indications for OST-HER2 (Listeria monocytogenes) in Solid Tumors, Including Canines CAMBRIDGE, Md., Nov. 17, 2020 /PRNewswire/ -- OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and…Super UserNovember 23, 2020
News What monoclonal antibodies are – and why we need them as well as a vaccine When President Trump was diagnosed with COVID-19, one of the cutting-edge experimental therapies he received…Super UserNovember 23, 2020
News Maryland Today | UMD Ranked in Top 10 for Innovation and Entrepreneurship Education for Sixth Straight Year For the sixth consecutive year, the University of Maryland (UMD) earned a top 10 ranking…Super UserNovember 23, 2020
News SR One Completes Spin-out from GSK and Closes First Fund at $500 Million | Business | thedailytimes.com SR One, a trans-Atlantic biotech venture capital firm, announced today the close of its first…Super UserNovember 23, 2020
News The state of AI in 2020 | McKinsey The results of this year’s McKinsey Global Survey on artificial intelligence (AI) suggest that organizations…Super UserNovember 23, 2020
News Protecting Our Future: Spurring Innovation to Support Pediatric Preparedness With COVID-19, we’ve seen our preparedness response tested, and the question remains, how can we…Super UserNovember 23, 2020
News BLUE KNIGHT™ Symposium In seeking to combat emerging infectious diseases and other 21st century health threats, the path…Super UserNovember 23, 2020
News Join the Force: An Info Session on JLABS @ Washington, DC and the BLUE KNIGHT™ Collaboration BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced…Super UserNovember 23, 2020
News Private S. Korean investments in biohealth to reach 10 trillion won by 2023 – EconoTimes South Korea’s leading biologics companies will invest hundreds of billions of won to building additional…Super UserNovember 23, 2020
News Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020, a Novel Experimental Cell Therapy for Glioblastoma | Business Wire ROCKVILLE, Md. & DURHAM, N.C.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering…Super UserNovember 23, 2020